Niapelf (Paliperidone)

Paliperidone, the active ingredient in Niapelf, is an atypical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients, helping to manage psychotic symptoms and improve functional outcomes. The formulation is designed for depot administration, providing sustained plasma concentrations over several weeks.

GNH USA supplies Niapelf as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is used in the management of psychotic disorders, targeting dopamine and serotonin pathways.

Schizophrenia: reduces positive and negative symptoms and helps maintain stability. Schizoaffective disorder: alleviates mood and psychotic components. Maintenance therapy for schizophrenia: provides long‑acting control of relapse risk.

Paliperidone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Weight gain: increase in body mass index. - Somnolence: feeling of drowsiness or fatigue. - Extrapyramidal symptoms: tremor, rigidity, or restlessness. - Elevated prolactin: menstrual disturbances or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, potentially irreversible. - Seizures: rare occurrence, especially at high plasma levels.

When prescribing Niapelf, clinicians should consider several safety and handling precautions.

Metabolic monitoring: assess weight, glucose, and lipid levels regularly. Cardiovascular assessment: evaluate blood pressure and ECG for QT prolongation. Movement disorders: watch for signs of akathisia or dystonia. Renal function: adjust use in patients with impaired clearance. Hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Paliperidone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase paliperidone levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Medications that prolong QT interval (e.g., haloperidol, quinidine): risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): additive sedation. - Antihypertensives: possible additive blood pressure lowering. - Anticholinergic agents: may mask extrapyramidal symptoms. - Serotonergic drugs (e.g., SSRIs, tramadol): monitor for serotonin syndrome.